Donanemab-Azbt
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Comparison table: Amyloid beta-directed antibodies for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: September 08, 2026
Comparison table: Amyloid beta-directed antibodies for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026
Comparison table: Drugs for Alzheimer's disease dementia.
Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026
PET in Neurology: Imaging Pathology, Metabolism, and Disease Progression
Journal: Brain and nerve = Shinkei kenkyu no shinpo
Published: February 17, 2026
The Advanced Therapeutics for Alzheimer's Disease Review Board: A multidisciplinary model to facilitate safe access to amyloid-targeting therapies in general neurology across the Sutter Health system.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: February 09, 2026
Elecsys - a second blood test for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: January 23, 2026
Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: December 31, 2025
Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood-Brain Barrier in Targeted Treatment of Alzheimer's Disease.
Journal: Pharmaceutics
Published: December 27, 2025
Amyloid-Beta Immunotherapies for Alzheimer's Disease: Current Progress.
Journal: Current Alzheimer research
Published: November 23, 2025
In brief: Updates for lecanemab (Leqembi) for Alzheimer's disease.
Journal: The Medical letter on drugs and therapeutics
Published: November 05, 2025
Last Updated: 11/08/2026